Some authors proposed that MRI accuracy was higher in HER2-positive and triple-negative breast cancer and less in luminal breast cancer (9, 19, 26), whereas others proposed that MRI accuracy significantly decreased in patients treated with HER2-targeted agents, resulting in an overestimation of the extent of the residual lesions due to the increase in neovascular permeability (27), which may lead to overtreatment in this subtype. The gene discussed is ERBB2; the disease is breast carcinoma.